文献速递免疫规划

DNA初免/MVTT加强免疫方案使用HIV-1嵌合Gag抗原增强抗原特异性免疫应答的效力

DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
PubMed 文献 · Vaccine · 2018-06-28

研究在小鼠中比较DNA初免(体内电穿孔)联合复制型修饰痘苗天坛株(MVTT)载体疫苗加强的异源免疫方案与同源免疫方案,使用HIV-1嵌合Gag抗原。异源DNA/MVTT方案诱导更广泛持久的Gag特异性多功能细胞毒性CD8+ T细胞和更高抗Gag抗体滴度,并保护小鼠抵御EcoHIV和AB1-Gag肿瘤攻击。

要点

  • DNA初免/MVTT加强的异源方案在小鼠中诱导比同源方案更广泛、更强的Gag特异性免疫应答。
  • 异源方案产生更高频率的广反应性、多功能性、长寿命细胞毒性CD8+ T细胞及更高抗Gag抗体滴度。
  • 该方案诱导针对EcoHIV和AB1-Gag攻击的保护,作者认为具进一步开发前景。

核心结论

  • 使用两种安全载体的异源DNA/MVTT方案诱导更强的保护性Gag特异性免疫,作者认为有进一步开发以增强抗HIV-1免疫的前景。

研究设计与样本

  • 小鼠免疫原性研究:以表达HIV-1嵌合Gag抗原的DNA疫苗经体内电穿孔初免,再用复制型修饰痘苗天坛株(MVTT)载体疫苗加强,并与DNA或MVTT同源免疫比较。

主要发现

  • 与DNA或MVTT同源免疫相比,异源DNA/MVTT免疫小鼠中广反应性、Gag特异性、多功能性、长寿命细胞毒性CD8+ T细胞频率更高,抗Gag抗体滴度亦升高。
  • DNA/MVTT异源免疫诱导针对EcoHIV和间皮瘤AB1-Gag攻击的保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HIV-1 diversity and latent reservoir are the major challenges for the development of an effective AIDS vaccine. It is well indicated that Gag-specific CD8+ T cells serve as the dominant host immune surveillance for HIV-1 control, but it still remains a challenge for vaccine design to induce broader and stronger cytotoxic T cell immunity against the virus. Genetic variation of the HIV-1 gag gene across different clades is one of the reasons for the reduction of antigenic epitope coverage. Here, we report an immunization strategy with heterologous vaccines expressing a mosaic Gag antigen aimed to increase antigenic breadth against a wider spectrum of HIV-1 strains. Priming using a DNA vaccine via in vivo electroporation, followed by boosting with a live replication-competent modified vaccinia TianTan (MVTT) vectored vaccine, elicited greater and broader protective Gag-specific immune responses in mice. Compared to DNA or MVTT homologous immunization, the heterologous DNA/MVTT vaccination resulted in higher frequencies of broadly reactive, Gag-specific, polyfunctional, long-lived cytotoxic CD8+ T cells, as well as increased anti-Gag antibody titer. Importantly, the DNA/MVTT heterologous vaccination induced protection against EcoHIV and mesothelioma AB1-Gag challenges. In summary, the stronger protective Gag-specific immunity induced by the heterologous regimen using two safe vectors shows promise for further development to enhance anti-HIV-1 immunity. Our study has important implications for immunogen design and the development of an effective HIV-1 heterologous vaccination strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu W, Wong YC, Chen SMY, et al. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses. Vaccine. 2018. PMID: 29961605. doi:10.1016/j.vaccine.2018.06.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。